About Us

Mr LIU Gexin

Chairman of the Board and non-Ｅxecutive Director

Mr. LIU Gexin,  was appointed as a Director and the chairman of the Board in November 2016 and March 2022, respectively. He was redesignated as our non-Ｅxecutive Director on February 15, 2023. He is mainly responsible for overseeing the management and strategic development of the Group. 

Mr. Liu is the founder of Kelun Pharmaceutical and has served as the chairman of Kelun Pharmaceutical since its establishment. From November 2020 to October 2022, he served as a director of Kelun Research Institute. In addition, Mr. Liu currently has also held positions in a number of subsidiaries of Kelun Group, including (i) the chairman of Sichuan Kelun Industry Group Co., Ltd.; (ii) the chairman of Chengdu Qingshan Likang Pharmaceutical Co., Ltd.; (iii) the chairman of Yili Chuanning Biotechnology Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 301301); and (iv) a director of Chengdu Huaxi Clinical Research Co., Ltd.. 

Mr. Liu obtained his bachelor's degree in pharmaceutics from Dalian Railway Medical College (currently known as Dalian University) in China in October 1975. Mr. Liu obtained his Ｍaster's degree in cardiovascular pharmacology from Chongqing Medical College (currently known as Chongqing Medical University) in China in June 1984. Mr. Liu also obtained his another Ｍaster's degree in political economics from Southwest Normal University (currently known as Southwest University) in China in July 2003

Dr. GE Junyou

General Manager, Ｅxecutive Director

Dr. GE Junyou, aged 50, was appointed as a Director in February 2022. He was redesignated as our Ｅxecutive Director on February 15, 2023. Dr. Ge was appointed as the chief operation officer of the Company in February 2021 and the general manager of the Company in March 2022. He is mainly responsible for overall corporate and business strategies of our Group and making key business and operational decisions of our Group. Mr. Ge has also served as a director of KLUS PHARMA since December 1, 2021, an Ｅxecutive director of Sichuan Konas since November 17, 2021, and an Ｅxecutive director and a manager of Kelun-Biotech Research Center since March 30, 2023. 

From July 1994 to December 1997, Dr. Ge served as a production and R&D officer of Shanghai Yan’an Pharmaceutical Factory. From January 1998 to April 2000, he served as a deputy manager of the technical department of Shanghai Hengshoutang Pharmaceutical Co., Ltd.. From April 2000 to January 2004, he served as a GMP compliance manager of Boehringer Ingelheim Pharmaceutical Co., Ltd. (Shanghai). From January 2004 to January 2006, he served as an assistant to general manager of Zhejiang Hisun Pharmaceutical Co., Ltd., a company listed on the Shanghai Stock Exchange (stock code: 600267). From January 2006 to May 2007, he served as a quality manager of Ratiopharm GmbH. Dr. Ge joined Kelun Pharmaceutical in June 2007 and served as a deputy general manager from July 2009 to February 2021, where he was mainly responsible for leading the quality management of Kelun Group. Prior to formally joining our Group as our chief operating officer in February 2021, by virtue of his position and responsibilities as a deputy general manager of Kelun Pharmaceutical, Dr. Ge has been familiar with our Group’s business and operations and had been in charge of the quality control of Kelun Group (including that of our Company) since 2018. Dr. Ge led the establishment and construction of GMP system of our Group and has been involved in the production quality management of our Group, including the quality control of our production management department, production quality department, equipment engineering department, and warehouse and logistics department. He also participated in our Group’s CMC activities, team management and building, promotion of production projects, and decision-making for facility construction and procurement.

Dr. Ge obtained his bachelor’s degree in pharmacy from Shanghai Medical School (currently known as Shanghai Medical College Fudan University) in China in July 1994. He obtained his Ｍaster’s degree in pharmaceutical engineering from East China University of Science and Technologythrough on-the-job learning in China in November 2008. He also obtained his doctoral degree in Biology and Medicine from Fudan University in China in January 2017.

Dr. WANG Jingyi

Ｅxecutive Director

Dr. WANG Jingyi , aged 62, was appointed as a Director of our Company in November 2016 and was redesignated as an Ｅxecutive Director on February 15, 2023. Dr. Wang had been serving as the general manager of our Company and ceased to act as the general manager in March 2022. He is mainly responsible for the overall strategic planning and development of the Group. 

From December 1999 to March 2001, Dr. Wang served as a research assistant professor in medicine of University of Arkansas for Medical Sciences. He formerly served as a vice general manager of QILU Pharmaceutical Co., Ltd. and the president of QILU Pharmaceutical and Drug Research Institute. From November 2012 to February 2021, Dr. Wang served as a director of Kelun Pharmaceutical. 

Dr. Wang is currently one of the editorial board members of China Journal of New Drugs, an evaluation expert for national science and technology awardsand major national science and technology projects for major new drug creation. Dr. Wang has also been awarded the second prize of National Science and Technology Progress Awardby The State Council, PRC for two times in recent years.

Dr. Wang obtained his bachelor’s degree in medical medicine from China Medical University (中国医科大学) in China in August 1983. He obtained his Ｍaster’s degree and doctoral degree in lemology and medical molecular virology from The Fourth Military Medical University (解放军第四军医大学) in China in November 1988 and July 1991, respectively.

Mr. LIU Sichuan

Non-Ｅxecutive Director

Mr. LIU Sichuan, aged 39, was appointed as a Director in November 2016. He was redesignated as our non-Ｅxecutive Director on February 15, 2023. He is mainly responsible for overseeing the management and strategic development of the Group.

Mr. Liu joined Kelun Pharmaceutical and served as the assistant of chairman in 2007. He has been serving as a director of Kelun Pharmaceutical since May 2009 and general manager of Kelun Pharmaceutical since September 2015. Currently he has also held positions in a number of subsidiaries of Kelun Group, including (i) a director of Chengdu Qingshan Likang Pharmaceutical Co., Ltd. since June 2012; (ii) a manager and Ｅxecutive director of Chengdu Kelun Chuaicai Enterprise Management Co., Ltd since May 2020; (iii) a director of Yili Chuanning Biotechnology Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 301301), since June 2020; (iv) a director of Sichuan Kelun Industry Group Co., Ltd. since September 2021; and (v) a manager and Ｅxecutive director of Chengdu Kelun Jingchuan Technology Co., Ltd. since November 2021.

Mr. Liu obtained his Ｍaster’s degree in international business from the University of Leeds in the United Kingdom in August 2007.

Mr. FENG Hao

Non-Ｅxecutive Director

Mr. FENG Hao, aged 43, was appointed as a Director in February 2021. He was redesignated as our non-Ｅxecutive Director on February 15, 2023. He is mainly responsible for overseeing the management and strategic development of the Group.

Mr. Feng has been serving as: (i) a deputy general manager and secretary of board of directors of Kelun Pharmaceutical since April 2014; and (ii) a non-Ｅxecutive director of SSY Group Limited, a company listed on the Stock Exchange (stock code: 02005) since November 2017.

From July 2002 to August 2003, Mr. Feng served as a tutor at the School of Economics at Huazhong University of Science and Technology. From December 2004 to January 2005, Mr. Feng served as an analyst at the Actuarial Division of Taiping Life Insurance Company Limited. From December 2005 to December 2006, he served as an actuarial advisory consultant at Watson Wyatt Consultancy (Shanghai) Ltd. From January 2007 to August 2007, he served as a senior manager at the investment banking division of Ping An Securities Limited. From September 2007 to January 2014, he served as a business director at the investment banking division of Sinolink Securities Co. Ltd.

Mr. Feng obtained his bachelor’s degree in finance from Huazhong University of Science and Technology in China in June 2002. Mr. Feng also obtained his Ｍaster’s degree in financial mathematics from Heriot-Watt University in the United Kingdom in November 2005.

Mr. ZENG Xuebo

Non-Ｅxecutive Director

Mr. ZENG Xuebo, aged 37, was appointed as a Director in July 2022. He was redesignated as our non-Ｅxecutive Director on February 15, 2023. He is mainly responsible for overseeing the management and strategic development of the Group.

Formerly he served as a manager and was then promoted as a director of Shenzhen Zhongyi Yingtai Venture Capital Co., Ltd.. From June 2015 to July 2016, he served as a deputy director of Shenzhen Investment Holdings Donghai Investment Co., Ltd.. From August 2016 to July 2019, he served as a director and was then promoted as a vice president of Aiqi Venture Capital Management (Shenzhen) Co., Ltd. He has served as a vice president of Hexie Zhuorui (Zhuhai) Investment Management Co., Ltd. since November 2020.

Currently he also holds positions in various companies, including (i) a director of Shandong Bestcomm Pharmaceutical Company Limited; (ii) a director of Hang Zhou Sciwind Biosciences Co., Ltd.; (iii) a director of Shanghai Model Organisms Center, Inc., a company listed on the Shanghai Stock Exchange (stock code: 688265), since September 2022; and (iv) a director of Chiral Quest (Suzhou) Co., Ltd.

Mr. Zeng obtained his bachelor’s degree in pharmacy from Qinghai Minzu University in China in July 2009.

Mr. LI Dongfang

Non-Ｅxecutive Director

Mr. LI Dongfang, aged 35, was appointed as a Director in February 2022. He was redesignated as our non-Ｅxecutive Director on February 15, 2023. He is mainly responsible for overseeing the management and strategic development of the Group.

From August 2011 to March 2015, Mr. Li served as an analyst of Goldman Sachs (Asia) L.L.C. He has been serving as an Ｅxecutive director of SDIC Investment Management Co., Ltd. since August 2015, where he is responsible for equity investment.

Mr. Li obtained his bachelor’s degree and Ｍaster’s degree in electronic commerce and finance from University of International Business and Economics in China in July 2009 and July 2011, respectively. He has been a Chartered Financial Analyst since June 2015.

Dr. ZHENG Qiang

Independent Non-Ｅxecutive Director

Dr. ZHENG Qiang, aged 62, was appointed as an independent non-Ｅxecutive Director on February 15, 2023 with effect from the Listing Date. He is mainly responsible for supervising and providing independent advice on the operation and management of our Group.Dr. Zheng joined the Peking University in 2005, and he has been serving as a professor and doctoral supervisor in industrial engineering and management in Peking University.

Dr. Zheng obtained his bachelor’s degree in physics from Peking University in China in July 1983. Dr. Zheng obtained his Ｍaster’s degree in physics from Graduate School of Chinese Academy of Sciences (currently known as University of Chinese Academy of Sciences in China in August 1986. He also obtained his doctoral degree in physics from Temple University in the United States in June 1989.

Dr. TU Wenwei

Independent Non-Ｅxecutive Director

Dr. TU Wenwei, aged 56, as appointed as an independent non-Ｅxecutive Director on February 15, 2023 with effect from the Listing Date. He is mainly responsible for supervising and providing independent advice on the operation and management of our Group.

Dr. Tu successively served as a lecturer and attending doctor at the department of paediatrics of Children’s Hospital, Chongqing Medical University and a postdoctoral researcher fellow in the department of pediatrics at the Stanford University School of Medicine in the United States before 2006. Dr. Tu has served as a professor in the department of paediatrics & adolescent medicine, Li Ka Shing Faculty of Medicine at The University of Hong Kong (the “HKU”) since June 2015. Dr. Tu also held various positions, such as the assistant dean of the Li Ka Shing Faculty of Medicine since October 2011 and an associate professor since June 2009 at the department of paediatrics & adolescent medicine since joining HKU in 2006.

Dr. Tu obtained his bachelor’s and Ｍaster’s degrees in medicine sciences from Chongqing Medical University in the PRC in July 1989 and December 1992, respectively. He obtained his doctoral degree in philosophy from HKU in December 1999. Dr. Tu has received a series of awards including several Prize of Science and Technology Progress. He was also recognized as a Changjiang scholar chair professor in pediatrics by Ministry of Education of PRC in April 2016.

Dr. JIN Jinping

Independent Non-Ｅxecutive Director

Dr. JIN Jinping, aged 50, as appointed as an independent non-Ｅxecutive Director on February 15, 2023 with effect from the Listing Date. She is mainly responsible for supervising and providing independent advice on the operation and management of our Group.

Dr. Jin serves as an associate professor in the Law School, Peking University. She has been serving as an independent director of Beijing Oriental Jicheng Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 002819), since July 2018 and an independent director of China Automotive Engineering Research Institute Co., Ltd., a company listed on the Shanghai Stock Exchange (stock code: 601965), since January 2020.

Dr. Jin obtained her bachelor’s degree, Ｍaster’s degree and doctoral degree in law from Peking University in China in July 1995, July 2001 and June 2004, respectively.

Dr. LI Yuedong

Independent Non-Ｅxecutive Director

Dr. LI Yuedong, aged 46, was appointed as an independent non-Ｅxecutive Director on February 15, 2023 with effect from the Listing Date. She is mainly responsible for supervising and providing independent advice on the operation and management of our Group.

Dr. Li joined the Southwestern University of Finance and Economics in 2011 and she has been serving as a doctoral supervisor in Auditing in Southwestern University of Finance and Economics since January. She has been serving as (i) an independent director of Chengdu Leejun Industrial Co., Ltd. since July 2021, a company listed on the Shenzhen Stock Exchange (stock code: 002651); (ii) an independent director of Chengdu Sino Microelectronics Technology Co., Ltd. since September 2021; (iii) an independent director of Ya’an Baitu High Tech Materials Co., Ltd. since September 2022; (iv) an independent director of Chengdu Zhimingda Electronics Co., Ltd., a company listed on Shanghai Stock Exchange (stock code: 688636), since November 2022; and (v) an independent director of Chengdu Shengbang Seals Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 301233), since November 2022. In addition, Dr. Li also served as (i) an independent director of Kelun Group from June 2015 to June 2021; (ii) an independent director of Chengdu Hi-Tech Development Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 000628) from June 2015 to June 2022; (iii) an independent director of Sichuan Fengsheng Paper Technology Co., Ltd. from December 2019 to December 2022; and (iv) an independent director of Sichuan Neautus Traditional Chinese Medicine Co., Ltd. from January 2020 to February 2023.

Dr. Li obtained her bachelor’s degree in economics from Chongqing Business College (currently known as Chongqing Technology and Business University) in China in July 2000. Dr. Li obtained her Ｍaster’s degree in accountancy from Georgia College & State University in the United States in May 2004. She also obtained her doctoral degree in business administration from Southwestern University of Finance and Economics in China in January 2011. Dr Li was certified as a public accountant by the Guam Board of Accountancy in August 2015. She also completed audit training course in the United Nations in June 2020. Dr. Li has received a series of awards and recognition. She was recognized as an internationalized high-end accounting talent by Ministry of Finance of the PRC in December 2021.